BioXcel Therapeutics, Inc.
BTAIQ- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001720893
No open-market purchases or sales by BioXcel Therapeutics, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $8.69M in total; Oaktree Capital is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +7 vs. previous quarter
- 47
- 13F valueReported value at the end of Q2 2026
- $8.69M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding BTAIQ, Q2 2026
1 superinvestor reports holding BioXcel Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Oaktree Capital
Howard Marks
<0.1%
BioXcel Therapeutics, Inc.'s share of the portfolio
- Shares
- 1,380,248
- Value
- $1.95M
Latest insider trades
Open-market purchases and sales by BioXcel Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2026 (view filing) | May 20 | 2 days | Yocca FrankChief Scientific Officer | SSale | −6.84K | $1.09 | −$7.46K | −20.7%26.2K after | 10b5-1 |
| May 22, 2026 (view filing) | May 20 | 2 days | Rodriguez JavierSee Remarks | SSale | −6.56K | $1.08 | −$7.08K | −19.7%26.8K after | 10b5-1 |
| May 22, 2026 (view filing) | May 20 | 2 days | Steinhart Richard IChief Financial Officer | SSale | −6.84K | $1.09 | −$7.46K | −20.7%26.3K after | 10b5-1 |
| May 22, 2026 (view filing) | May 20 | 2 days | Mehta VimalCEO and President | SSale | −19.4K | $1.09 | −$21.2K | −21.8%69.6K after | 10b5-1 |
| Dec 17, 2024 (view filing)6:10 PM ET | Dec 16 | 1 day | O'Neill VincentSee Remarks | SSale | −165 | $0.3523 | −$58.13 | −0.8%20.0K after | 10b5-1 |
| Dec 17, 2024 (view filing)6:08 PM ET | Dec 16 | 1 day | Mehta VimalCEO and President | SSale | −3.12K | $0.3629 | −$1.13K | −5.0%59.6K after | 2 lots10b5-1 |
| Dec 17, 2024 (view filing)6:06 PM ET | Dec 16 | 1 day | Steinhart Richard IChief Financial Officer | SSale | −577 | $0.3587 | −$206.98 | −2.7%20.9K after | 2 lots10b5-1 |
| Dec 17, 2024 (view filing)6:04 PM ET | Dec 16 | 1 day | Rodriguez JavierSee Remarks | SSale | −430 | $0.3559 | −$153.02 | −1.7%24.4K after | 2 lots10b5-1 |
| Dec 17, 2024 (view filing)6:03 PM ET | Dec 16 | 1 day | Yocca FrankChief Scientific Officer | SSale | −430 | $0.3531 | −$151.82 | −1.5%28.9K after | 2 lots10b5-1 |
| Oct 3, 2024 (view filing) | Oct 3 | Same day | Wiley Matthew T.Chief Commercial Officer | SSale | −6.27K | $0.55 | −$3.45K | −24.8%19.0K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in BioXcel Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Millennium Management LLC | 2,114,710 | $2.98M | 0.00% | +177,950+9.2% | Added |
| Oaktree Capital Management LPSuperinvestorOaktree Capital | 1,380,248 | $1.95M | 0.04% | +1,139,060+472.3% | Added |
| Vanguard Capital Management LLC | 919,545 | $1.30M | 0.00% | +712,206+343.5% | Added |
| Oaktree Fund Advisors, LLC | 245,585 | $346.3K | 0.60% | +202,672+472.3% | Added |
| Geode Capital Management, LLC | 242,251 | $341.9K | 0.00% | +12,083+5.2% | Added |
| BlackRock, Inc. | 179,433 | $253.0K | 0.00% | +95,151+112.9% | Added |
| UBS Group AG | 158,065 | $222.9K | 0.00% | +105,277+199.4% | Added |
| Citadel Advisors LLC | 149,220 | $210.4K | 0.00% | +149,220 | New |
| Vanguard Fiduciary Trust Co | 136,937 | $193.1K | 0.00% | +52,016+61.3% | Added |
| State Street Corp | 92,118 | $129.9K | 0.00% | 00.0% | Unchanged |